A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China.
Liu W, Zhao D, Liu T, Niu T, Song Y, Xu W, Jin J, Cai Q, Huang H, Li Z, Hou M, Zhang H, Zhou J, Hu J, Shen J, Shi Y, Yang Y, Zhang L, Zhao W, Ding K, Qiu L, Tan H, Zhang Z, Liu L, Wang J, Xu B, Zhou H, Gao G, Xue H, Bai O, Feng R, Huang X, Yang H, Yan X, Zeng Q, Liu P, Li W, Mao M, Su H, Wang X, Xu J, Zhou D, Zhang H, Ma J, Shen Z, Zhu J.
Liu W, et al. Among authors: bai o.
Front Oncol. 2021 Nov 4;11:750323. doi: 10.3389/fonc.2021.750323. eCollection 2021.
Front Oncol. 2021.
PMID: 34804937
Free PMC article.